Complete remission of metastatic renal cell carcinoma to the bone with sunitinib.
Bone metastasis
Complete response
Renal cell carcinoma
Sunitinib
Journal
Urology case reports
ISSN: 2214-4420
Titre abrégé: Urol Case Rep
Pays: United States
ID NLM: 101626357
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
13
04
2020
accepted:
15
04
2020
entrez:
6
5
2020
pubmed:
6
5
2020
medline:
6
5
2020
Statut:
epublish
Résumé
Target agents such as tyrosine kinase inhibitors have improved renal cell carcinoma (RCC) patient outcomes. However, complete remission (CR) with target agents is rare. Furthermore, CR of bone metastasis is much less common. We report a case of CR in bone and lung metastatic RCC. Radical nephrectomy was performed first, and clear cell RCC was diagnosed. Thereafter, sunitinib was started, and bone and lung metastases resolved entirely after 8 months of treatment. Sunitinib therapy was discontinued after 2 years because of the adverse event of proteinuria. However, the patient has remained in CR for over 1 year after sunitinib cessation.
Identifiants
pubmed: 32368498
doi: 10.1016/j.eucr.2020.101213
pii: S2214-4420(20)30101-7
pii: 101213
pmc: PMC7184521
doi:
Types de publication
Case Reports
Langues
eng
Pagination
101213Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
None.
Références
J Clin Oncol. 2012 Feb 10;30(5):482-7
pubmed: 22231040
Ann Oncol. 2011 Apr;22(4):794-800
pubmed: 20937648
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
Anticancer Res. 2007 Mar-Apr;27(2):889-94
pubmed: 17465216
Eur Urol. 2016 Sep;70(3):469-75
pubmed: 26746623